EU Malaria Fund: Sanaria receives substantial investment into its proprietary malaria platform
On the occasion of the Annual Meeting of the American Society of Tropical Medicine and Hygiene approximately 4,900 global health professionals representing academia, government, and the private sector were informed about the latest investment of the EU Malaria Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005124/en/
https://www.controlmalaria.eu (Graphic: Business Wire)
The EU Malaria Fund is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.
On November 13, 2020, Sanaria received €12.9M for the development of two malaria vaccines, one malaria prophylactic, as well as an initial proof-of-concept for an oral SARS-CoV-2 vaccine.
Sanaria’s PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria. PfSPZ Vaccine elicits an immunological response in the body against the malaria pathogen, without the individual getting sick. This results in robust and durable protection. On the verge of Phase III clinical trials, PfSPZ Vaccine is positioned to be the world’s first malaria vaccine to receive marketing authorization. Sanaria’s second generation vaccine, Sanaria PfSPZ-CVac (Chemoprophylaxis Vaccine), focuses on increased potency and decreased costs. The funding also advances the research and development of human monoclonal antibodies from multiple candidates based on potency and manufacturability in order to provide immediate short-term protection against malaria. Finally, a portion of the funding will be used to advance OraCOV, an oral, self-administered vaccine candidate against COVID-19, based on Sanaria’s work in malaria.
Dr. Stephen L. Hoffman, Sanaria’s founder and CEO said, “We applaud the EU Malaria Fund for addressing this critical funding gap and we are grateful and honored to be the recipient of this investment.”
“We wholeheartedly welcome the efforts of Sanaria, who for many years have been at the forefront of innovation and are bringing novel concepts to the table potentially reducing the unacceptable burden of malaria,” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme at the online signature event.
Holm Keller, Co-Managing Director of EUMF and Chairman of kENUP Foundation said: “Sanaria has developed one of the most advanced malaria vaccine candidates worldwide. We hope that this investment will help towards the eradication of malaria “.
More information can be found at https://www.controlmalaria.eu
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lineage Logistics Enters the Polish Cold Storage Market With the Acquisition of Pago Sp. z o.o.1.12.2020 18:04:00 CET | Press release
Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced it has acquired Pago Sp. z o.o. (“Pago”), a leading warehousing, distribution and transport logistics provider in Poland from its current ownership, including Tönnies International Holding GmbH (“Tönnies”). The strategic acquisition marks the Company’s entrance into the Polish market and adds six exceptional assets to Lineage’s global network of temperature-controlled facilities. Lineage was founded and continues to be managed by Bay Grove Capital, LLC (“Bay Grove”), a principal investment firm dedicated to partnering with strong management teams to build long-term platform investments. Financial terms of the transactions were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005951/en/ The acquisition of Pago Sp. z o.o
Sumitomo SHI FW fluidized bed technology – upscaling thermochemical energy storage to a commercial level1.12.2020 17:47:00 CET | Press release
One of the largest obstacles in using renewable energy efficiently is the possibility to store energy on a large scale. SaltX Technology AB has partnered with Sumitomo SHI FW (SFW) to solve this in terms of heat energy. "The storage solution is like a "salt battery". It is based on a basic chemical process with a very common material, calcium oxide produced from limestone, with enhanced properties by our nanocoating process", explains Carl-Johan Linér, CEO of SaltX. Simplified, when calcium oxide reacts with water, it turns into calcium hydroxide and releases heat. Respectively, when calcium hydroxide is dried, it absorbs heat. SFW has designed a fluidized bed pilot reactor, which serves as the point of discharge, where the salt releases the heat. The new 100 kW reactor in SaltX's new testing installation in Sweden, near Stockholm, combines the performance of SaltX's patented nanocoated salt with SFW's fluidized bed technology. "SFW's technology has huge potential to take the salt batt
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets1.12.2020 17:00:00 CET | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina® Focus Panel, AmpliSeq™ for Illumina® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio. Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic report
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 16:01:00 CET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity
Andersen Global Adds Collaborating Firm in Azerbaijan1.12.2020 15:30:00 CET | Press release
Andersen Global expands into Azerbaijan by way of a Collaboration Agreement with independent Baku-based law firm MGB Law Offices, adding coverage and positioning the organization for further expansion between Europe and Asia. Founded in 1995, MGB Law Offices, which has ten lawyers, has been recognized by IFLR1000, Legal500 and Chambers and Partners as the leading law firm in Azerbaijan. Led by Managing Partner Ismail Askerov, the full-service firm offers solutions in various industries such as oil and gas, aviation, banking and finance, insolvency and restructuring, tax, privatization law and foreign investment. The firm’s client base includes blue-chip multinationals, international financial institutions, insurance companies, airlines, telecom companies and other business entities. “We are proud of our ability to consistently deliver best-in-class services, and our comprehensive solutions position us to be one of the most reputable law firms in the market by allowing us to meet the di
Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 15:00:00 CET | Press release
Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom